In November, 2022, Molecular detection of Department of Pathology passed the external quality control assessment of National Pathology Quality Control Center (PQCC) with high score again. The assessment items mainly consisted of verification of fluorescence in situ hybridization (FISH) including 4 genes, verification of detection of 6 gene mutations, verification of detection of BRCA1/2 gene mutation ctDNA sample, and next-generation sequencing (NGS) quality control item, respectively.
For the first time, NGS external quality control item was subject to PQCC assessment，since NGS was carried out in Department of Pathology at the end of 2021. With tremendous support from Director and the whole staff of the department, this item successfully passed PQCC assessment with high score, which significantly recognizes and inspires the work of Department of Pathology.
PQCC is the most authoritative quality control assessment institution for pathological laboratories across China. Since its establishment in 2011, PQCC has been devoted to improving the molecular pathological detection level in China and organizing multiple special programs to verify laboratory testing capability on a regular basis. External quality control assessment is a highly important standard and acts as the foundation of pathological precision medicine. Since its establishment, Molecular Pathology Laboratory of Department of Pathology has participated in PQCC laboratory quality control assessment for 10 consecutive years, and successfully passed all the assessment!
Currently, Department of Pathology can perform the following molecular testing: NGS, Sanger sequencing, PCR, digital PCR, FISH, circulating tumor cell (CTC) detection and 3D-HDRA, etc. Passing PQCC laboratory quality control assessment repeatedly affirms the capability of Department of Pathology in molecular detection process and result interpretation, which signifies a leap forward into the field of tumor gene detection by Department of Pathology in our hospital and provides individualized guidance for targeted treatment for more cancer patients.
